Nicholas Manusos is the founder of Kenai Therapeutics. Kenai Therapeutics has raised $100M in total funding. Latest round: Series A.
Nicholas Manusos is the Founding Chief Executive Officer and Co-founder of Kenai Therapeutics, a clinical-stage biotech company focused on induced pluripotent stem cell therapy for Parkinson's disease. He led the company through its transition to a clinical-stage organization and secured an $82 million Series A round in March 2024. Manusos has raised nearly $100 million in total dilutive and non-dilutive funding since the company's inception in early 2022.
Full founder directory · Investor directory · Company funding database · Fundraising library